Global pharmaceutical company Eli Lilly and Company (NYSE: LLY ) shares rose 3.4% in early trading after the company announced very positive Phase 3 trial results for its next-generation weight loss drug candidate retarglutide.
This triple agonist drug activates three hormone receptors (GIP, GLP-1 and glucagon) and met all primary and key secondary endpoints in patients with obesity and knee osteoarthritis. Headline data showed that the highest dose of retarglutide resulted in an average weight loss of up to 28.7% over 68 weeks, a result that significantly exceeded the efficacy of its existing blockbuster drug Zepbound.
Additionally, trials have shown significant improvements in pain and physical function. Investors viewed the successful trial as strong evidence of Eli Lilly’s deepening pipeline dominance in the large and rapidly expanding cardiometabolic health market, reinforcing the stock’s premium valuation.
After the initial jump, shares cooled to $1,015, up 2.3% from the previous close.
Is Now the Time to Buy Eli Lilly? Please access our full analysis report here.
Eli Lilly’s stock price is volatile, rising more than 5% 10 times last year. Against this backdrop, today’s move suggests the market sees the news as meaningful but won’t fundamentally change its view on the business.
The biggest jump we wrote about last year was eight months ago, when the stock jumped 15.3% on news that results from a Phase 3 trial showed its experimental drug Orforglipron performed significantly better in helping patients manage obesity and diabetes. The stock’s reaction showed investor optimism that, if approved, Eli Lilly could quickly scale up production and tap into the fast-growing diabetes and obesity markets.
Eli Lilly’s shares are up 30.4% since the beginning of the year, at $1,015 per share, and are near its 52-week high of $1,110 from November 2025. An investor who purchased $1,000 worth of Eli Lilly and Company stock 5 years ago would now be considering an investment worth $6,339.
The 1999 book Gorilla Game predicted that Microsoft and Apple would dominate technology. Its thesis? Identify platform winners early. Today, enterprise software companies embedding generative AI are becoming the new gorillas. Click here to access our special report that reveals a leader already cashing in on this wave.